Occurrence of Pancreatic Exocrine Insufficiency in Patients with Advanced Neuroendocrine Tumours Treated with Somatostatin Analogue Abstract #2819

Introduction: Neuroendocrine neoplasia (NENs) are heterogeneous tumours caracterized by a relatively indolent rate of growth. Usually, in G1 and G2 GEP-NENs, first-line therapy is SSAs, considering their efficacy, good safety profile, and antiproliferative effects. SSA treatment inhibits the production and excretion of pancreatic enzymes and PEI is known to be an adverse effect of SSA treatment.
Aim(s): Evaluated the occurrence of PEI in patients with advanced NENs treated with SSA
Materials and methods: An unicentric, observational, prospective study has been designed. Enrolled a continuous series of pts with advanced GI NENs tumours treated with SSA LAR. In order to evaluate the presence of EPI, the following blood tests were performed: FE-1 dosage, Vitamin D, PTH, HbA1C, Glycaemia, Serum Calcium, Total cholesterol and triglycerides. The FE-1 values were considered positive with <200 μg / g or U / L
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD Maria Rinzivillo

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2931 One-Stage Middle-Preserving Pancreatectomy: Indications and Outcomes
Introduction: Parenchyma-sparing surgical techniques are used in pancreatic surgery to preserve organ function. Middle-preserving pancreatectomy (MPP) may be an alternative to total pancreatectomy (TP) in benign/borderline disease that does not affect pancreatic body.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto
#2925 A Single Centre Experience of Open Surgery for Pancreatic Insulinomas on 88 Patients
Introduction: Insulinomas are functioning pancreatic neuroendocrine neoplasms (NENs), typically small and with a benign clinical course in more than 90% of cases.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto
#3045 Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with MEN1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort
Introduction: Pancreatic neuroendocrine tumors (pNETs) are the most lethal manifestation in patients with multiple endocrine neoplasia type 1 (MEN1). Tumor size is still regarded as the main prognostic factor and therefore used for surgical decision making.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: MD, MSc Dirk-Jan van Beek
#2733 Pancreatic Metastases Originating from Intestinal Neuroendocrine Tumours
Introduction: Pancreatic metastases are rare, accounting for 1 to 2% of pancreatic tumours. Data on pancreatic metastases of intestinal NETs are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Anja Rinke
#2990 Pitfalls in Glucagon-Like Peptide-1 Receptor Imaging
Introduction: Physiological pancreatico-duodenal DOTA-Exendin-4 uptake in the Brunner’s glands of the proximal duodenum occurs in Glucagon-like peptide-1 receptor (GLP-1R) imaging and is a known potential pitfall.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Antwi Antwi